CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • ASCO 2023 Preview — Partnering with Patients: The Cornerstone of Cancer Care and Research

    This weekend, the highly anticipated 2023 annual meeting of the American Society of Clinical Oncologists (ASCO) takes…
    June 1, 2023| Arthur N. Brodsky, PhD
  • ASCO 2022 Recap: Cancer Immunotherapy Updates

    Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought…
    June 13, 2022| Arthur N. Brodsky, PhD
  • ASCO 2022 Preview: The Latest Insights from the Front Lines of Cancer Immunotherapy

    CRI’s PRINCE Trial featured at ASCO22, along with sessions that highlight the latest clinical advances in checkpoint…

    June 2, 2022| Arthur N. Brodsky, PhD
  • ASCO21 Recap: Immunotherapy’s Continued Progress and Addressing Healthcare Disparities

    ASCO21 highlighted the latest immunotherapy advances in checkpoint inhibition and cell therapies, and addressed disparities in healthcare.

    June 9, 2021| Arthur N. Brodsky, PhD
  • Recapping ASCO20: The Next Horizons in Immunotherapy

    The 56th Annual ASCO Meeting highlighted advances in checkpoint immunotherapy, cell-based immunotherapies, and bispecific antibodies.

    June 4, 2020| Arthur N. Brodsky, PhD
  • ASCO20 Update: Considerations for Checkpoint Inhibitors Moving Forward

    Results unveiled at ASCO20 increased our understanding of checkpoint immunotherapy in a variety of cancers and circumstances.

    June 1, 2020| Arthur N. Brodsky, PhD
  • ASCO20 Update: Cellular Immunotherapies, Genomics, and COVID-19

    Several promising cellular immunotherapies were discussed at ASCO20, including those for solid cancers; plus updates on the cancer…

    May 31, 2020| Arthur N. Brodsky, PhD
  • ASCO20 Preview: Unite & Conquer – Accelerating Progress Together

    The ASCO20 Annual Meeting kicks off virtually on Friday, May 31—and advances in immunotherapy will be a…

    May 22, 2020| Arthur N. Brodsky, PhD
  • ASCO19 Recap: Caring for Every Patient, Learning from Every Patient

    ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…

    June 7, 2019| Arthur N. Brodsky, PhD
1 2 3 … 6
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute

Group of three cancer survivors

Your support saves lives

Double Your Impact Today

On #Immune2Cancer Day, your gift matched up to $50,000

Photo of Cancer Survivors: Brendan Connors, Karen Peterson, and Tom Vibert